CoChat

PFOS and Its Commercial Alternative, 6:2 Cl-PFESA, Induce Multidrug Resistance in Pancreatic Cancer

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Abstract

Per- and polyfluoroalkyl substances (PFAS), specifically perfluorooctanesulfonate (PFOS) and its alternative, 2-[(6-chloro-1,1,2,2,3,3,4,4,5,5,6,6-dodecafluorohexyl)oxy]-1,1,2,2-tetrafluoroethanesulfonic acid (6:2 Cl-PFESA), are associated with environmental health concerns and potential cancer progression. However, their impact on multidrug resistance (MDR) in pancreatic cancer (PC) chemotherapy remains unclear. Here, we employed drug-sensitivity assays, including IC 50 calculations, in vitro and in vivo models with various chemotherapeutics, and paclitaxel (PTX) as a representative agent, combined with transcriptomic/proteomic sequencing and clinical prognostic analysis, to identify MDR-related genes and validate their relevance, with the objective of establishing the correlation between PFOS/6:2 Cl-PFESA exposure and MDR in PC at molecular, cellular, and animal model levels. Our findings demonstrate that PFOS/6:2 Cl-PFESA exposure increases the drug IC 50 in three different PC cell lines for various chemotherapeutic agents. Compared with PFOS, 6:2 Cl-PFESA demonstrated a more pro-MDR effect on PC cells in vitro . In vivo experiments further revealed that PFOS/6:2 Cl-PFESA exposures significantly reduced the efficacy of PTX in PC, with inhibition rates dropping from 78.3% to 23.8%/6.1%, respectively ( p < 0.05). This effect was driven by the aberrant activation of the PI3K-ABCB1 pathway, with 6:2 Cl-PFESA demonstrating a stronger capacity to promote this signal pathway's ex…

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.est.4c08669

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Hong J., 2020, Am. J. Transl. Res., 12, 551

Cited by

See all 16

Metadata

Authors
Hong, J., Du, K., Zhang, W., Jiang, Y., Yu, H., Pan, T., Wu, T., Zhao, L., Du, W., Zheng, S.-S., Jin, H., Chen, Y., & Cao, L.
Affiliations
  • First Affiliated Hospital Zhejiang University (CN)
  • Zhejiang University (CN)
  • NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310003, PR China
  • Chinese Research Academy of Environmental Sciences (CN)
  • Kunming University of Science and Technology (CN)
  • Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, PR China
  • Zhejiang University of Technology (CN)
Corresponding author
  • Jin, Hangbiao
  • Chen, Yuanchen
  • Cao, Linping
Venue
Environmental Science & Technology
Published
2024-12-07
Volume
58
Issue
50
Pages
22027-22038
ISSN
  • 0013-936X (ISSN-L)
  • 1520-5851
OpenAlex
W4405130441
Cited by
16
References
77
Citations by year
2026: 12 · 2025: 4
FWCI
2.10
Type
journal article
Language
en
Open access
closed
Locations
  • Environmental Science & Technology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Fundamental Research Funds for the Central Universities (226-2024-00117)
  • National Natural Science Foundation of China (21806139, 42177390)
  • Innovative Research Groups of National Natural Science Foundation of China (81721091)
Topics
  • Physical Sciences › Environmental Science › Environmental Chemistry › Per- and polyfluoroalkyl substances research
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
PFOS, per- and polyfluoroalkyl substances, multidrug resistance, pancreatic cancer, paclitaxel, P-glycoprotein, chemotherapeutic drug resistance, PFAS alternatives, cancer risk assessment
MeSH terms
Animals, Fluorocarbons, Humans, Pancreatic Neoplasms, Alkanesulfonic Acids, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.